Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Melanoma 13Carcinoma, Squamous Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × talimogene laherparepvec × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡